Washington Dc, DCNCT06544499Now EnrollingIRB Ready

Immune Thrombocytopenia Clinical Trial in Washington Dc, DC

Access cutting-edge immune thrombocytopenia treatment through this clinical trial at a research site in Washington Dc. Study-provided care at no cost to qualified participants.

Sponsored by argenx

Quick Self-Assessment

See if you qualify for this Washington Dc location

Preparing your pre-screening questions...

Expert Care in Washington Dc

Access immune thrombocytopenia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related immune thrombocytopenia treatment provided free

Apply for This Washington Dc Location

Check if you qualify for this immune thrombocytopenia clinical trial in Washington Dc, DC

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Washington Dc

    Convenient for DC residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Washington Dc site if eligible
  4. 4Begin participation

About This Immune Thrombocytopenia Study in Washington Dc

The main purpose of this study is to look at the effect (efficacy) and safety of efgartigimod IV in participants with primary immune thrombocytopenia (ITP). After an up to 2 weeks screening period, eligible participants will be randomized in a 2:1 ratio to receive either efgartigimod IV or placebo IV, respectively during the double-blinded treatment period (DBTP). At the end of the treatment period (up to 24 weeks), all participants will receive efgartigimod IV during the first 52-week open-labe

Sponsor: argenx

Who Can Participate

Inclusion Criteria

Is at least 18 years of age and the local legal age of consent for clinical studies when signing the informed consent form (ICF).
Has documented baseline mean platelet count of \<30 x 10\^9/L before randomization
Has a documented duration of primary immune thrombocytopenia (ITP) of more than 12 months on the date of informed consent form (ICF) signature.
Has documented prior ITP treatment with at least 1 of the following treatments: corticosteroids, intravenous immunoglobulin (IVIg), anti-D immunoglobulin, thrombopoietin receptor agonist (TPO-RAs), or rituximab.
Has documented insufficient response to a prior ITP treatment (the specific criteria can be found in the protocol).
Has documented prior response defined as 1 platelet count of ≥50 × 109/L to at least 1 of the following ITP treatments in the 3 years before the date of ICF signature: prednisone, dexamethasone, other or nonspecified corticosteroids, IVIg, or anti-D immunoglobulin

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Washington Dc?

Yes, this clinical trial (NCT06544499) has an active research site in Washington Dc, DC that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Immune Thrombocytopenia Treatment Options in Washington Dc, DC

If you're searching for immune thrombocytopenia treatment options in Washington Dc, DC, this clinical trial (NCT06544499) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Washington Dc research site is actively enrolling participants for this clinical trial. You'll receive care from experienced immune thrombocytopenia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all immune thrombocytopenia clinical trials near you to find additional studies recruiting in your area.

More Multiple Myeloma Trials in Washington Dc, DC

See all multiple myeloma clinical trials recruiting in Washington Dc — not just this study.

Browse Multiple Myeloma Trials in Washington Dc →

Browse More Trials by Condition

Multiple Myeloma TrialsPulmonary Embolism TrialsThrombocytopenia TrialsIdiopathic Thrombocytopenic Purpura TrialsAll Conditions →

Ready to Join in Washington Dc?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Washington Dc, DC